Neuralink, Elon Musk's company, received FDA approval to expedite its vision technology, 'Blindsight,' through the regulatory process.
Science Corp., founded by Neuralink's former president, announced successful preliminary results from a clinical trial. The trial showed some vision restoration in patients with age-related macular degeneration.
Both companies aim to address widespread vision problems like macular degeneration using advanced brain-computer interface technology.